Meet IQ's Leadership
IQ's Board of Directors includes representatives from all IQ member companies, and is led by a Chair and Vice Chair.
Carl L. McMillian, PhD, IQ Consortium Chair
Dr. Carl L. McMillian currently holds the position of Vice President of Toxicology, Drug Disposition and PK/PD, a research unit that plays a crucial role in enabling delivery of Lilly’s R&D portfolio from all therapeutic areas of focus. Carl has over 20 years of industry experience as both a scientist and an administrative leader within Eli Lilly’s R&D organization. Prior to joining Lilly, he completed both his Bachelor’s (Pharmacy) and Ph.D (Medicinal Chemistry) at Auburn University (Auburn, AL). Additionally, he has held multiple internal roles involving R&D governance/portfolio management, strategic planning, operational oversight, and alliance oversight.
Carl serves as one of two Eli Lilly representatives on the Board of Directors of the IQ Consortium, an international association of pharmaceutical and biotechnology companies aiming to advance innovation and quality in the development of pharmaceutical products through scientifically-driven best practices and standards. Carl is also engaged in a number of industry and professional associations and is a recognized expert in non-clinical safety assessment, drug metabolism, and pharmacokinetics. He is also involved in a number of civic and community related activities.
Margaret Faul, PhD, IQ Consortium Vice-Chair
Margaret received her B.Sc. and M.Sc degrees from University College Dublin, Ireland. In 1987 she moved to the United States where she received her Ph.D. degree in Synthetic Organic Chemistry from Harvard University with Professor David A. Evans. In 1993 Margaret joined the Chemical Process group at Eli Lilly and Company and in 2003 went to Amgen Inc, in Thousand Oaks, CA where she is currently Vice President of Drug Product Technologies within the Process Development organization.
During her 25-year career Margaret has leveraged her technical experience to support programs across all stages of development from preclinical to commercial focused on the process development and supply of drug substance and drug product for clinical trials and the commercial market. Margaret has experience working with Commercial Manufacturing Organizations worldwide and an ability to work with partners during licensing activities to ensure seamless integration and development of programs with the partner company. Margaret has a strong knowledge of GMP, regulatory and compliance issues as they relate to the development of pharmaceutical products. She has received numerous awards in recognition of her leadership and mentorship including the Earle B. Barnes Award for Leadership in Chemical Research Management from Dow Chemical Company and the American Chemical Society and a HBA Rising Star Award.
At Amgen Margaret has invested significant effort in evolving a Green chemistry culture focused on implementation of greener and more sustainable chemical processes towards the development of novel drug substances. These efforts resulted in Amgen being awarded the Presidential Green Chemistry Challenge Award in 2017 in recognition of their work in development of an improved Green Process for Commercial Manufacture of Etelcalcetide.
Margaret has a strong scientific reputation and has invested significantly in supporting external scientific efforts. She is a member of the Board of Directors of the International Consortium for Innovation and Quality in the Pharmaceutical Industry and Chair of the Enabling Technologies Consortium. Margaret has a strong publication record being an author/co-author of more than 150 peer reviewed publications, presentations and patents. Margaret has served as a symposium organizer and session chair for several major process chemistry events and is has been a member of the Editorial boards for Science of Synthesis, Organic Synthesis, Journal of Organic Chemistry and Organic and Biomolecular Chemistry.